The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 1×
“Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively in cancer cells in vitro and in vivo, with little or no effect on normal cells (Pitti et al., 1996; Ashkenazi et al., 1999; Keane et al., 1999; Walczak et al., 1999; Lawrence et al., 2001).”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Apoptosis control by death and decoy receptors
Ashkenazi, A., & Dixit, V. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80034-9 · Cited by 1,288
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
FADD: Essential for Embryo Development and Signaling from Some, But Not All, Inducers of Apoptosis
Yeh, W.-C., Pompa, J. L. D. L., McCurrach, M. E., Shu, H.-B., Elia, A. J., Shahinian, A., Ng, M., Wakeham, A., Khoo, W., Mitchell, K., et al. (1998) · Science · doi:10.1126/science.279.5358.1954 · Cited by 893
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Histone acetylases and deacetylases in cell proliferation
Kouzarides, T. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80006-9 · Cited by 601
Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL
MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., & Alnemri, E. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25417 · Cited by 557
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Kischkel, F. C., Lawrence, D. A., Tinel, A., LeBlanc, H., Virmani, A., Schow, P., Gazdar, A., Blenis, J., Arnott, D., & Ashkenazi, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105102200 · Cited by 536
Nakano, K., Mizuno, T., Sowa, Y., Orita, T., Yoshino, T., Okuyama, Y., Fujita, T., Ohtani-Fujita, N., Matsukawa, Y., Tokino, T., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22199 · Cited by 395
Self-citationTakimoto, R., & El-Deiry, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203489 · Cited by 360
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325
Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites
Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., & Sakai, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7786 · Cited by 288
Self-citationGibson, S. B., Oyer, R., Spalding, A. C., Anderson, S. M., & Johnson, G. L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.205-212.2000 · Cited by 259
Histone deacetylase as a therapeutic target
Krämer, O. H., Göttlicher, M., & Heinzel, T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00438-6 · Cited by 257
Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies
Griffith, T. S., Rauch, C. T., Smolak, P. J., Waugh, J. Y., Boiani, N., Lynch, D. H., Smith, C. A., Goodwin, R. G., & Kubin, M. Z. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2597 · Cited by 241
FADD Is Required for DR4- and DR5-mediated Apoptosis
Kuang, A. A., Diehl, G. E., Zhang, J., & Winoto, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000284200 · Cited by 232
Huang, L., Sowa, Y., Sakai, T., & Pardee, A. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203963 · Cited by 209
Self-citationCovalent modifications of histones: expression from chromatin templates
Davie, J. R. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80138-x · Cited by 199
Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E., & Bhalla, K. (2000) · Blood · doi:10.1182/blood.v96.12.3900 · Cited by 196
Yoshida, M., & Beppu, T. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90030-4 · Cited by 185
Ohtsuka, T., Buchsbaum, D., Oliver, P., Makhija, S., Kimberly, R., & Zhou, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206290 · Cited by 159
Koornstra, J. J., Kleibeuker, J. H., van Geelen, C. M. M., Rijcken, F. E. M., Hollema, H., de Vries, E. G. E., & de Jong, S. (2003) · The Journal of Pathology · doi:10.1002/path.1364 · Cited by 153
Mariani, S. M., Matiba, B., Armandola, E. A., & Krammer, P. H. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.221 · Cited by 145
Mühlenbeck, F., Haas, E., Schwenzer, R., Schubert, G., Grell, M., Smith, C. W., Scheurich, P., & Wajant, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.33091 · Cited by 143
Hirose, T., Sowa, Y., Takahashi, S., Saito, S., Yasuda, C., Shindo, N., Furuichi, K., & Sakai, T. (2003) · Oncogene · doi:10.1038/sj.onc.1207091 · Cited by 137
Self-citationShigeno, M., Nakao, K., Ichikawa, T., Suzuki, K., Kawakami, A., Abiru, S., Miyazoe, S., Nakagawa, Y., Ishikawa, H., Hamasaki, K., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206139 · Cited by 134
Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL‐R2 gene 1
Yoshida, T., Maeda, A., Tani, N., & Sakai, T. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02947-7 · Cited by 133
Self-citationMeng, R. D., & El‐Deiry, W. S. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5073 · Cited by 130
Sun, S., Yue, P., Wu, G. S., El‐Deiry, W. S., Shroot, B., Hong, W. K., & Lotan, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202543 · Cited by 118
Zhang, X. D., Gillespie, S., Borrow, J. M., & Hersey, P. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00509-4 · Cited by 115
Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest
Wu, G. S., Burns, T. F., McDonald, E. R., Meng, R. D., Kao, G. D., Muschel, R. J., Yen, T. J., & El‐Deiry, W. S. (1999) · Oncogene · doi:10.1038/sj.onc.1203025 · Cited by 114
He, Q., Lee, D. I., Rong, R., Yu, M., Luo, X., Klein, M., El‐Deiry, W. S., Huang, Y. K., Hussain, A., & Sheikh, M. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205345 · Cited by 96
Neužil, J., Swettenham, E., & Gellert, N. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.074 · Cited by 87
p15INK4b in HDAC inhibitor‐induced growth arrest
Hitomi, T., Matsuzaki, Y., Yokota, T., Takaoka, Y., & Sakai, T. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01186-4 · Cited by 71
Self-citationHe, Q., Luo, X., Huang, Y. K., & Sheikh, M. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205897 · Cited by 58
Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities
Jang, Y., Park, K. S., Chung, H. Y., & Kim, H. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00680-8 · Cited by 39
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“c-FLIP, an inhibitor of the death receptor pathway, was downregulated by HDACi (Nakata et al., 2004; Peart et al., 2005; Rosato and Grant, 2005; Sutheesophon et al., 2005).”
BackgroundInfluentialApoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Metadata
- Authors
- Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., & Sakai, T.
- Venue
- Oncogene
- Published
- 2004-06-21
- Volume
- 23
- Issue
- 37
- Pages
- 6261-6271
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2087057471
- Cited by
- 271
- References
- 47
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.